United Therapeutics Scores $45 Million To Develop Novel Virology Treatments
This article was originally published in The Pink Sheet Daily
United Therapeutics Corp. gets a $45 million tranched grant from the U.S. National Institute of Allergy and Infectious Disease to develop broad-spectrum compounds against influenza and Dengue.
You may also be interested in...
The start-up supplied few details about its arrangement with its Big Pharma partner, but receives cash as it prepares to take a promising influenza therapy into the clinic.
The company tells skeptical analysts it will pursue a limited monotherapy label based on a single positive Phase III study in the wake of a second combination trial failure.
Six-year-old Inviragen may be the biotech of the future.